0001659073-25-000001.txt : 20250911 0001659073-25-000001.hdr.sgml : 20250911 20250910200114 ACCESSION NUMBER: 0001659073-25-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20250911 DATE AS OF CHANGE: 20250910 EFFECTIVENESS DATE: 20250911 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Galvanize Therapeutics, Inc. CENTRAL INDEX KEY: 0001659073 ORGANIZATION NAME: EIN: 474075510 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-557260 FILM NUMBER: 251306961 BUSINESS ADDRESS: STREET 1: 1531 INDUSTRIAL ROAD CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-268-4252 MAIL ADDRESS: STREET 1: 1531 INDUSTRIAL ROAD CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: Gala Therapeutics, Inc. DATE OF NAME CHANGE: 20151123 D 1 primary_doc.xml X0708 D LIVE 0001659073 Galvanize Therapeutics, Inc. 3200 Bridge Parkway Redwood City CA CALIFORNIA 94065 650-268-4252 DELAWARE Gala Therapeutics, Inc. Corporation true Doug Godshall c/o Galvanize Therapeutics, Inc. 3200 Bridge Parkway Redwood City CA CALIFORNIA 94065 Executive Officer Director Seth Harrison c/o Galvanize Therapeutics, Inc. 3200 Bridge Parkway Redwood City CA CALIFORNIA 94065 Director Jonathan Waldstreicher c/o Galvanize Therapeutics, Inc. 3200 Bridge Parkway Redwood City CA CALIFORNIA 94065 Executive Officer Antoine Papiernik c/o Galvanize Therapeutics, Inc. 3200 Bridge Parkway Redwood City CA CALIFORNIA 94065 Director Zack Scott c/o Galvanize Therapeutics, Inc. 3200 Bridge Parkway Redwood City CA CALIFORNIA 94065 Director David Lewis c/o Galvanize Therapeutics, Inc. 3200 Bridge Parkway Redwood City CA CALIFORNIA 94065 Director Steve Anheier c/o Galvanize Therapeutics, Inc. 3200 Bridge Parkway Redwood City CA CALIFORNIA 94065 Executive Officer Biotechnology Decline to Disclose 06b false 2025-07-07 false true false 0 141066486 96130465 44936021 For the total amount sold: $60,467,996.83 new money; $35,662,468.47 conversion of debt false 28 0 0 0 false Galvanize Therapeutics, Inc. /s/ Steve Anheier Steve Anheier CFO 2025-09-10